Company
Agomab Therapeutics
- Biotech
HQ: Antwerpen
Overview
Agomab develops biopharmaceutical therapies for fibro-inflammatory conditions, targeting the TGFß/ALK5 pathway and advancing candidates for fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis.